SWITCHING OF FLUORESCENCE LIFETIME UPON FUOROBODY BINDING

荧光体结合时荧光寿命的切换

基本信息

项目摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Abstract Dr. Andrew Bradbury of the Bioscience Division is developing a new class of fluorescent ligand termed 'fluorobodies', which are GFP molecules to which a series of ligand-recognition loops have been added at one end, producing a quasi-antibody binding site (1). Such fluorobodies would be much more useful if there was some change in the fluorescence signal upon binding. We will investigate whether binding of fluorbodies to their target ligand induces a measurable change in the fluorescence lifetime of the GFP. If the bound and unbound molecules had two different fluorescence lifetimes, this would essentially be a switch that detected binding. We will measure the fluorescence lifetime of fluorobodies bound to microspheres exposed to differing concentrations of ligand, and determine if we can detect a difference in shift in lifetime upon binding. Dr. Bradbury's group has engineered several different GFP molecules that vary in the robustness of their folding, and we may be able to select larger lifetime effects of ligand binding by using GFPs having less stable protein folding. Background We are developing a new class of fluorescent ligand termed 'fluorobodies'. These are GFP molecules into which antibody binding loops have been inserted. In its present incarnation, single loops corresponding to the third hypervariable region of the heavy chain variable region have been inserted into a specific site in GFP. A library of such fluorobodies has been created using random HCDR3's derived from lymphocytes (see attached publication in appendix) and specific binders selected by phage display. Even though only single loops are displayed within the GFP, he has been able to select binders recognizing a number of different targets with affinities in the high nanomolar range (400-1000nM). This is significantly higher than the affinities obtained by traditional peptide phage display, and the selected binders retain their fluorescence. In fact, the determination of the affinity was carried out using flow cytometry with antigen coupled to polystyrene beads and the detected fluorescence arising from fluorobody binding. Approach Fluorobodies would be much more useful if there was some change in the fluorescence signal upon binding. Although we are attempting to develop binders based on fluorescent proteins that change their fluorescence upon binding, an alternative approach is to determine whether other fluorescence properties change upon binding. We will investigate whether binding of fluorobodies to their target ligands induces a measurable change in the fluorescence lifetime of the GFP. If the bound and unbound molecules had two different fluorescence lifetimes, this would essentially be a switch that detected binding. We will take an evolving approach to the implementation and application of this technology. First, we will measure the fluorescence lifetimes of fluorobodies bound to microspheres and exposed to differing concentrations of ligand, and determine if we can detect a difference in shift in lifetime upon binding. This work can be done with the upgraded version of the separated PS cytometer. Second, we will determine if we can engineer fluorobodies with enhance lifetime changes upon binding. We have already engineered several different fluorescent proteins that vary in the robustness of their folding, and we may be able to select larger lifetime effects of ligand binding by using GFPs having less stable protein folding. This application will take good advantage of the capability of measuring multiple lifetimes simultaneously, to be implemented on both the phase sensitive and integrated phase-spectral instruments. Third, we will determine whether we can develop fluorobodies with different spectral emission spectra, e.g. YFP, BFP. This would then open the potential to use combinations of fluorobodies with differing emission spectra to simultaneously to quantitate bound and unbound forms of several ligands in cells and bead-based assays. If this technology is successful, it will provide a potentially very powerful biological application for the integrated phase-spectral instrument, which would provide the ability to distinguish spectral emission and lifetime on a mixture of many fluorobodies.
这个子项目是众多研究子项目之一

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ANDREW BRADBURY其他文献

ANDREW BRADBURY的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ANDREW BRADBURY', 18)}}的其他基金

Enhancing crystallization with binding partners, symmetry and diversity
通过结合伙伴、对称性和多样性增强结晶
  • 批准号:
    8471721
  • 财政年份:
    2012
  • 资助金额:
    $ 3.34万
  • 项目类别:
Enhancing crystallization with binding partners, symmetry and diversity
通过结合伙伴、对称性和多样性增强结晶
  • 批准号:
    8666771
  • 财政年份:
    2012
  • 资助金额:
    $ 3.34万
  • 项目类别:
Enhancing crystallization with binding partners, symmetry and diversity
通过结合伙伴、对称性和多样性增强结晶
  • 批准号:
    8268582
  • 财政年份:
    2012
  • 资助金额:
    $ 3.34万
  • 项目类别:
A high throughput pipeline to select renewable recombinant polyclonal antibodies
选择可再生重组多克隆抗体的高通量管道
  • 批准号:
    8335448
  • 财政年份:
    2011
  • 资助金额:
    $ 3.34万
  • 项目类别:
ANALYSIS AND SORTING OF BACTERIAL LIBRARY EXPRESSING GFP
表达GFP的细菌文库分析与排序
  • 批准号:
    8361751
  • 财政年份:
    2011
  • 资助金额:
    $ 3.34万
  • 项目类别:
SWITCHING OF FLUORESCENCE LIFETIME UPON FUOROBODY BINDING
荧光体结合时荧光寿命的切换
  • 批准号:
    8361766
  • 财政年份:
    2011
  • 资助金额:
    $ 3.34万
  • 项目类别:
A high throughput pipeline to select renewable recombinant polyclonal antibodies
选择可再生重组多克隆抗体的高通量管道
  • 批准号:
    8533069
  • 财政年份:
    2011
  • 资助金额:
    $ 3.34万
  • 项目类别:
A high throughput pipeline to select renewable recombinant polyclonal antibodies
选择可再生重组多克隆抗体的高通量管道
  • 批准号:
    8223869
  • 财政年份:
    2011
  • 资助金额:
    $ 3.34万
  • 项目类别:
A high throughput pipeline to select renewable recombinant polyclonal antibodies
选择可再生重组多克隆抗体的高通量管道
  • 批准号:
    8520300
  • 财政年份:
    2011
  • 资助金额:
    $ 3.34万
  • 项目类别:
ANALYSIS AND SORTING OF BACTERIAL LIBRARY EXPRESSING GFP
表达GFP的细菌文库分析与排序
  • 批准号:
    8169387
  • 财政年份:
    2010
  • 资助金额:
    $ 3.34万
  • 项目类别:

相似海外基金

University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
  • 批准号:
    10073243
  • 财政年份:
    2024
  • 资助金额:
    $ 3.34万
  • 项目类别:
    Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
  • 批准号:
    10752129
  • 财政年份:
    2024
  • 资助金额:
    $ 3.34万
  • 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
  • 批准号:
    2339201
  • 财政年份:
    2024
  • 资助金额:
    $ 3.34万
  • 项目类别:
    Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
  • 批准号:
    MR/Y008693/1
  • 财政年份:
    2024
  • 资助金额:
    $ 3.34万
  • 项目类别:
    Research Grant
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
  • 批准号:
    23K14783
  • 财政年份:
    2023
  • 资助金额:
    $ 3.34万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
  • 批准号:
    23KJ0394
  • 财政年份:
    2023
  • 资助金额:
    $ 3.34万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
  • 批准号:
    10076445
  • 财政年份:
    2023
  • 资助金额:
    $ 3.34万
  • 项目类别:
    Grant for R&D
PLA2G2D Antibodies for Cancer Immunotherapy
用于癌症免疫治疗的 PLA2G2D 抗体
  • 批准号:
    10699504
  • 财政年份:
    2023
  • 资助金额:
    $ 3.34万
  • 项目类别:
Genetic adjuvants to elicit neutralizing antibodies against HIV
基因佐剂可引发抗艾滋病毒中和抗体
  • 批准号:
    10491642
  • 财政年份:
    2023
  • 资助金额:
    $ 3.34万
  • 项目类别:
Novel Immunogens to Elicit Broadly Cross-reactive Antibodies That Target the Hemagglutinin Head Trimer Interface
新型免疫原可引发针对血凝素头三聚体界面的广泛交叉反应抗体
  • 批准号:
    10782567
  • 财政年份:
    2023
  • 资助金额:
    $ 3.34万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了